Linde plc (EU)

  • WKN: A2DSYC
  • ISIN: IE00BZ12WP82
  • Land: Irland

Nachricht vom 25.10.2021 | 17:30

Linde plc: Linde Declares Dividend in Fourth Quarter 2021

DGAP-News: Linde plc / Key word(s): Dividend
25.10.2021 / 17:30
The issuer is solely responsible for the content of this announcement.

Linde Declares Dividend in Fourth Quarter 2021

Guildford, UK, October 25, 2021 - Linde plc (NYSE: LIN; FWB: LIN) announced its Board of Directors has declared a quarterly dividend of $1.06 per share.

The dividend is payable on December 17, 2021 to shareholders of record on December 3, 2021.

 

About Linde
Linde is a leading global industrial gases and engineering company with 2020 sales of $27 billion (€24 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet.

The company serves a variety of end markets including chemicals & refining, food & beverage, electronics, healthcare, manufacturing and primary metals. Linde's industrial gases are used in countless applications, from life-saving oxygen for hospitals to high-purity & specialty gases for electronics manufacturing, hydrogen for clean fuels and much more. Linde also delivers state-of-the-art gas processing solutions to support customer expansion, efficiency improvements and emissions reductions.

For more information about the company and its products and services, please visit www.linde.com

Contacts:  
Investor Relations
Juan Pelaez
Phone: +1 203 837 2213
Email: juan.pelaez@linde.com
Media Relations
Anna Davies
Phone: +44 1483 244705
Email: anna.davies@linde.com


25.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Neufassung der Dividendenpolitik der Allianz SE

02. Dezember 2021, 20:33

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021